SPP 1234

Drug Profile

SPP 1234

Alternative Names: SPP1234

Latest Information Update: 16 Jul 2010

Price : $50

At a glance

  • Originator Speedel Group
  • Developer Speedel
  • Class Antihypertensives; Cardiovascular therapies
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 16 Jul 2010 Discontinued - Phase-0 for Hypertension in Switzerland (PO)
  • 10 Jul 2008 Speedel Group has been acquired by Novartis
  • 31 Mar 2008 Phase-0 for Hypertension in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top